

BETULA projekt d.o.o.


Bonds offer

Open opportunity for investment /
low investment in big project



Investment opportunity

- BETULA projekt d.o.o. offers bonds
- Financing of research and development
- Small investment for big potential
- Big pharma is interested in this project



Bonds offer

€2,0M



**Interest
rate**

8%

godišnje



**Bond
maturity**

3 years



**Minimal
subscription**

€1.000



Bonds offer – BETULA projekt d.o.o.

BETULA projekt d.o.o. – issues / offers bonds

- Link: <https://betulaprojekt.com/obveznice/>
- Smart investment, controlled risks, secure return of principal
- Human goal (development of better therapy)

Target issuance
amount
EUR 2,000,000

Bond maturity
3 years

Repayment of principal
At the end of period

Interest rate
8% annual, fixed

Interest payment
Annually

Minimum subscription
EUR 1,000

Nominal value per bond
EUR 1,000


PHARMACEUTICAL COMPOSITION

New Generation of Medicines

Technology which enables the controlled release of a drug from the formulation.

PATENTS. THE PLATFORM. ADDED VALUE. HIGHER REVENUES. BLOCKBUSTERS.

Problem – Uncontrolled therapy, uncontrolled administration of drugs




Solution– The controlled release of a drug from the formulation

Novelty – number and the order of coatings

RESULT

- **Formulation** – a lot of particles
 - DRC / drug resin complex + layers
- **Pharmaceutical composition** -
 - enables **controlled and site specific** release of drug from the formulation
- **Technology** – spray granulation
 - modification – number / order of coatings



Model of particle (DRC + layers)

Patent application WO2012136816 (at national phases – 90 countries)


Patent application – WO201236816

- EP application
- EP divisional application
- EA application
- US application
- others (China, Japan, India...)
- granted patents
- global project



Competition

**Example -
novel
levodopa**
(antiparkinsonic)



Competitors	Duodopa	Existing oral formulations	Novel formulation
Price per year	50,000 Euros or more	1,000 Euros	3,000 - 5,000 Euros
Administration	parenteral	oral	oral
Features	unacceptable application	causes side effects	well controlled release
Rating of CR	excellent	bad	very good
Evaluation	<ul style="list-style-type: none"> ⊖ Expensive ⊖ Very inconvenient ⊕ Highly effective 	<ul style="list-style-type: none"> ⊕ Low cost ⊕ Convenient ⊖ Ineffective 	<ul style="list-style-type: none"> ⊕ Price acceptable ⊕ Convenient ⊕ Very Effective

The Platform - Usable for drugs with N

Duodopa

Hypertension

morphine

Depression

olanzapine

Viagra

sildenafil

Parkinson`s disease

tramadole

Sinemet

risperidone

Epilepsy

levodopa

Value Proposition



Users



Benefits

Patients

- better drug treatments
- better therapy
- better quality of life



- therapeutic – lower side effects
- economic – saving money
- business – staying on job / working

Health insurances / payers

- will ensure better treatments
- rationalisation of costs
- lower costs



- therapeutic – better healthcare
- economic - saving money (long-term)
- business – better results

Pharmaceutical company

- will produce better products
- good business opportunity
- higher market share



- **added value** – higher price and profit
- revenues in billion / **blockbusters**
- **The Platform**

Market Opportunity & Risks

Market

→ *European and global*

Blockbusters (past and future)

→ *Revenues in billion / Large PH company*

The Platform

→ *Usable to all drugs containing N (nitrogen)*

Business Model



Licensing (Model 1 of commercialization)

- cooperation with large pharmaceutical company
 - **patents**, fast realization, **higher prices**, **blockbusters**
-



Production (Model 2 of commercialization)

- outsourced production, later own production
 - higher costs, slower realization, longer exploitation
-



Next proceedings

- completing of package for commercialization / licensing
- **small trials** (known main and additional substances)

Commercialization & Marketing

Licensing - Model 1

...to large PH company

- need for novel products
- crisis in PH industry
- lack of good inventions
- **this is good opportunity**
- resources, **files**, network

Production - Model 2

...outsourced production

- need for better therapy
- novel technology developed
- **small trials**
- **bioavailability**
- **fast** commercialization

Financial Projections



Licensing - Model 1

- revenues in **billion**
- **Blockbusters**
- **The Platform**
- **added value**
- life extension for old generic drugs
- **higher prices**
- **higher revenues / profit**

Production – Model 2

- SME - commercialization
- outsourced production
- own production (SME)
- need partnering
- need funding
- slower realization
- less revenues
- less profit

Who we are?



**Zdravko
Dokuzović, PhD**

Researcher, inventor,
technologist,
earlier patents



**Ljiljana
Sović Brkičić**


Researcher, inventor,
patent applicant,
idea, business strategy



**Cvjetko
Brkičić**

Patent applicant,
business experience,
investment

Team – 95 years of experience; 15 years on this project; 36,500 hours of work (this project)



BLC pharmaceuticala d.o.o.

Croatia, Zagreb, Kralja Zvonimira 82
<http://www.pharmaceutica.blc.hr/>

- Ljiljana Sović Brkičić
- ljiljana.sovic@gmail.com
- pharmaceutica@blc.hr

Points



Novel technology / New generation of medicines

- developed
 - patents granted up to the year 2032 (+ 5 years additional)
-



The Platform

- usable to different drugs
 - usable to all drugs containing nitrogen (N)
-



Important / novel technology is applicable

- generics - **added value**, new generation of medicines
- novel drugs – **to prolong patent protection**